Actavis hasreceived FDA approval for Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg,8mg, and 12mg, a generic equivalent to Requip XL (GlaxoSmithKline).Distribution of the product has commenced.

Requip XL isan orally administered, non-ergoline dopamine agonist indicated for thetreatment of the signs and symptoms idiopathic Parkinson’s disease. The precisemechanism of action of ropinirole as a treatment for Parkinson’s disease isunknown, although it is believed to be due to stimulation of postsynapticdopamine D2-typereceptors within the caudate-putamen in the brain.

For moreinformation call (973) 993-4500 or visit www.actavis.us.